CEL-SCI

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Arch Capital

Arch Capital Group Ltd. Deposit Shs Repr 1/1000th 5.45 % Non-Cum Pfd Shs Series F

AMC Networks

Altus Power

Apogee Enterprises

ASOS PLC

Avantis Real Estate ETF

BHP Billiton

Bill.com

BWX Technologies

Civitas Resources

Chipotle

YieldMax COIN Option Income Strategy ETF

CorMedix

CoStar Group

Diageo

Federal Realty Investment Trust

First Solar

Genworth Financial

Hewlett Packard

In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, Hewlett Packard Enterprise, Vertex Pharmaceuticals, and several others. Readers are encouraged to engage with the new analysts, share thoughts on their picks, and join the conversation.

Stock Picks From Seeking Alpha's October 2024 New Analysts

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--FDA's ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO2024--CEL-SCI's Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group.

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO24--CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 Congress.

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--The UK's Medicines & Healthcare Products Regulatory Agency grants CEL-SCI a pediatric waiver for Multikine.

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2024 financial results, as well as key recent clinical and corporate developments.

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $10.8 million offering.

CEL-SCI Announces Closing of $10.8 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $10.8 million offering .

CEL-SCI Announces Pricing of $10.8 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI's phase 3 population analysis for upcoming confirmatory registration study in head & neck cancer demonstrates well balanced patient population.

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI appoints Robert Watson as Chairperson of the Board.

CEL-SCI Appoints Robert Watson as Chairperson of the Board

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced the Company's Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT” at the International Drug Discovery Science & Technology (IDDST) 20th Annual Congress in Budapest, Hungary on Tuesday, June 18, 2024. Dr. Talor presented during the Cancers/Tumors session which he Chaired along with Dr.

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Dr. Giovanni Selvaggi, who has brought several oncology drugs to market, joins CEL-SCI as Clinical Advisor.

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2024 financial results.

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer.

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI appoints Mario Gobbo to its Board of Directors.

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

NEW YORK--(BUSINESS WIRE)--Channel V Media (CVM), a communications strategy and PR firm that builds market momentum for both established enterprises and emerging venture‑backed innovators, today announced the expansion of its 16-year content marketing practice. The company will build on its core competency of creating and executing on lead generation content strategies with the introduction of B2B video and podcasting offerings. Leading this expansion will be new Director of Content, Gabriella.

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI's LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology.

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation issues letter to shareholders.

CEL-SCI Corporation Issues Letter to Shareholders

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results.

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $7.75 million public offering of common stock.

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces pricing of $7.75 million public offering of common stock.

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI completes commissioning of its Multikine manufacturing facility for commercial scale production of head & neck cancer drug.

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

News for CEL-SCI Stock (CVM)